10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC)
- Resource Type
- Authors
- Manon Pillai; Shien Chow; Fiona Thistlethwaithe; Andrea Spencer-Shaw; Victoria Galvis; Robert E. Hawkins; Rebecca Leach; Elizabeth Keene; Kevin Chan
- Source
- Journal of Clinical Oncology. 34:e16085-e16085
- Subject
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Standard of care
business.industry
Sunitinib
urologic and male genital diseases
medicine.disease
female genital diseases and pregnancy complications
First line treatment
Clinical trial
Pazopanib
03 medical and health sciences
Single centre
030104 developmental biology
0302 clinical medicine
Renal cell carcinoma
030220 oncology & carcinogenesis
Internal medicine
medicine
Intensive care medicine
business
medicine.drug
- Language
- ISSN
- 1527-7755
0732-183X
e16085Background: Sunitinib (S) and Pazopanib (P) have become the standard of care in the management of mRCC supported by clear therapeutic benefits in clinical trials. We set out to evaluate and c...